Research programme: carbapenemase inhibitors - The Medicines CompanyAlternative Names: RPX 7307; RPX 7381; RPX 7400
Latest Information Update: 06 Oct 2015
At a glance
- Originator The Medicines Company
- Mechanism of Action Beta lactamase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections
Most Recent Events
- 15 Sep 2015 Preclinical trials in Bacterial infections in USA (unspecified route)